Welcome to our dedicated page for Biotricity news (Ticker: BTCY), a resource for investors and traders seeking the latest updates and insights on Biotricity stock.
Biotricity Inc. (BTCY) delivers innovative medical technology solutions focused on AI-powered cardiac monitoring and chronic disease management. This news hub provides investors and healthcare professionals with essential updates on the company’s advancements in remote patient care.
Access timely press releases covering regulatory milestones, clinical study results, and strategic partnerships with healthcare institutions. Stay informed about product developments like the Bioflux cardiac monitoring system and consumer-focused Biolife platform, which combine medical-grade accuracy with AI-driven analytics.
Our curated news collection features earnings reports, technology patent announcements, and market expansion updates. Bookmark this page for verified information about BTCY’s progress in transforming cardiac care through connected health solutions.
Biotricity, Inc. (NASDAQ:BTCY) announced its participation in the 34th Annual Roth Conference from March 13-15, 2022, in Dana Point, California. This follows a strong fiscal third quarter, reporting a 93% year-over-year revenue growth and its highest cash position. The company is now taking preorders for Biotres, a new FDA-cleared wireless cardiac monitoring device aimed at the $5.7 billion market for cardiac arrhythmia monitoring. The device enhances long-term ECG data collection, expected to ship starting April 1, 2022.
Biotricity (NASDAQ:BTCY) has announced the commencement of pre-orders for its new Biotres device, a three-lead ECG monitoring system aimed at early detection of cardiac arrhythmias. Following recent FDA clearance, pre-orders started on February 23, 2022, with shipping scheduled for April 1, 2022. The Biotres device aims to disrupt the existing cardiac monitoring market, valued at approximately $5.7 billion, by providing continuous ECG data and remote uploading capabilities, enhancing diagnostic speed and efficiency.
Biotricity (BTCY) reported Q3 FY22 financial results with a remarkable 93% year-over-year revenue increase to $1.93 million, outpacing the 40% increase in SG&A. The company's cash position reached a historic $16.8 million. Despite a net loss of $7.34 million due to one-time expenses, adjusted loss is $6.0 million. Biotricity anticipates continued triple-digit revenue growth for the full year, fueled by the launch of innovative products like Bioheart and the FDA-cleared Biotres, expanding its addressable market significantly.
SWK Holdings Corporation (Nasdaq: SWKH) updated its portfolio performance for the second half of 2021, highlighting new financings including $10 million to MolecuLight and $12 million to Biotricity (NASDAQ: BTCY). CEO Winston Black noted that 2022 aims to restore deal origination to historical levels. Enteris BioPharma's partnership with Cara Therapeutics is advancing with a $5 million milestone payment. Additionally, Biolase (NASDAQ: BVS) anticipates a 44-47% revenue increase for the fourth quarter. SWK focuses on providing flexible financing solutions to small and mid-sized life science companies.
Biotricity (NASDAQ:BTCY) is set to release its third quarter fiscal 2022 financial results on February 14, 2022, after the market closes. Management will discuss the results during a conference call on February 15, 2022, at 4:15 p.m. EST. The company anticipates 2022 as a breakout year, emphasizing the commercial launch of Bioheart and FDA clearance for Biotres. Biotricity focuses on remote health monitoring and chronic care management, aiming to enhance preventive and personal care for patients.
Biotricity, Inc. (NASDAQ:BTCY) has received 510(k) clearance from the FDA for its Biotres cardiac monitoring device, targeting the $2 billion holter market.
This innovative device allows continuous 3-channel ECG recordings for lower-risk patients, with features including a rechargeable battery, wireless connectivity, and user-friendly design. Biotres expands Biotricity's Total Addressable Market from $1 billion to $5.7 billion, with sales expected to begin on April 1, 2022. The CEO emphasizes its potential to enhance cardiac care and reduce costs.
Biotricity Inc. (NASDAQ:BTCY) has launched its Bioheart heart monitor system on Amazon.com, enhancing consumer access to advanced cardiac monitoring without a prescription. Priced at $199, the device is available for a limited introductory price of $149. The Bioheart offers continuous 24/7 data collection, advanced analytics, and innovative features like retrospective snapshots of heart data. This expansion not only opens new revenue streams for Biotricity but also targets a $1.24B market. The product aims to transform cardiac health monitoring through a virtual cardiac clinic ecosystem.
Biotricity Inc. (NASDAQ:BTCY) has successfully completed a $12 million non-convertible debt financing with SWK Funding LLC to replace existing debt and support inventory and annual recurring revenue (ARR) subscriptions. The financing includes a five-year term with an interest-only period of two years, leading to a 40% balloon payment at maturity. This capital infusion strengthens Biotricity's balance sheet without diluting equity shareholders and positions the company for upcoming product launches in 2022.
Biotricity (NASDAQ:BTCY) has released its December 2021 CEO Shareholder Letter, outlining key milestones and growth strategies for 2022. The Company reports a record quarterly revenue of $1.81 million, representing a 143% year-over-year increase. Significant achievements include its recent uplisting to Nasdaq, aimed at attracting institutional investors and enhancing liquidity. The shareholder letter highlights the successful commercialization of the Biokit and outlines future goals, including the launch of innovative cardiac monitoring solutions.
Biotricity (NASDAQ:BTCY) has launched Bioheart, an innovative heart monitor that allows users to access continuous heart monitoring technology directly via a smartphone app. Bioheart targets a growing market valued at
